Table 4.
Analysis of 2nd treatment initiated in the past 12 months as a function of the ECOG score, age of patients and location of metastases
| TOTAL | Age | ECOG | Location of metastases | ||||||
|---|---|---|---|---|---|---|---|---|---|
| < 60 yrs | 60–70 yrs | > 70 yrs | 0–1 | 2–4 | B | V ± B | C ± | ||
| N = 801 (%) | N = 406 (%) | N = 297 (%) | N = 98 (%) | N = 633 (%) | N = 162 (%) | N = 449 (%) | N = 697 (%) | N = 146 (%) | |
| TT only | 51 | 53 | 52 | 40** | 54* | 38 | 53 | 53 | 42 |
| T-DM1 | 47 | 50 | 49 | 31** | 51* | 33 | 48 | 49 | 39** |
| Trastuzumab | 2 | 2 | 1 | 4 | 1 | 3 | 2 | 1 | 1 |
| Trastuzumab + lapatinib | 1 | < 1 | 2 | 4* | 2 | 1 | 1 | 2 | |
| CT and TT and no HT | 36 | 36 | 35 | 36 | 35 | 38 | 32 | 35 | 46* |
| Capecitabine + lapatinib | 16 | 16 | 17 | 10 | 16 | 13 | 13 | 15 | 25* |
| Vinorelbine + trastuzumab | 7 | 8 | 5 | 11 | 6 | 11* | 6 | 7 | 9 |
| Capecitabine+trastuzumab | 4 | 4 | 4 | 2 | 3 | 6 | 4 | 3 | 3 |
| Paclitaxel+trastuzumab | 3 | 2 | 2 | 5 | 2 | 5 | 3 | 3 | 2 |
| ++Docetaxel+trastuzumab+pertuzumab | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 4* | |
| CT only | 8 | 9 | 6 | 12* | 6 | 18* | 8 | 8 | 8 |
| Capecitabine | 2 | 2 | 2 | 3 | 1 | 6* | 3 | 2 | 1 |
| Vinorelbine | 1 | 1 | 4* | 1 | 3* | 1 | 1 | 2 | |
| CA/CE | 1 | 2 | < 1 | 1 | 1 | 1 | 1 | 1 | |
| HT and TT and no CT | 5 | 2** | 6 | 10* | 5 | 5 | 7* | 4 | 4 |
| Trastuzumab+non-steroidal AI | 3 | 1 | 3 | 7* | 3 | 1 | 4 | 2 | 1 |
| Lapatinib+non-steroidal AI | 1 | < 1 | 1 | 1 | < 1 | 3* | 1 | 1 | 2 |
| CT and TT and HT | < 1 | 1 | 1 | < 1 | 1 | < 1 | |||
B bone, V ± B visceral ± bone, C ± cerebral ± others, CT chemotherapy, TT targeted therapy, HT hormonotherapy, AI aromatase inhibitors
* Value is significantly higher than the comparator group